Biogen Inc logo

Biogen Inc

MXN 5825.00 (+1.7%) Dec 2
P/E:
15.22
P/B:
3.37
Market Cap:
MXN 824.61B ($ 42.52B)
Enterprise V:
MXN 857.62B ($ 44.23B)
Volume:
109.00
Avg Vol (2M):
239.00
Also Trade In:
Volume:
109.00
Market Cap MXN:
824.61B
Market Cap $:
42.52B
PE Ratio:
15.22
Avg Vol (2-Month):
239.00
Enterprise Value MXN:
857.62B
Enterprise Value $:
44.23B
PB Ratio:
3.37
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Financials (Next Earnings Date:2023-02-03 Est.)

MEX:BIIB's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 211,372.796
EPS (TTM) (MXN) 396.849
Beta -0.94
Volatility % 31.7
14-Day RSI 94.26
14-Day ATR (MXN) 23.821396
20-Day SMA (MXN) 5601.4555
12-1 Month Momentum % 9.24
52-Week Range (MXN) 3880 - 5825
Shares Outstanding (Mil) 144

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Document Form Filing Date
No Filing Data

Biogen Inc Analysis

Share your research